News and Announcements
Xerion is pleased to announce the launch of their Pre-IPO funding round
- Published August 12, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Xerion is undertaking a Pre-IPO raising of $2.7M at $0.40 cents per share with an attaching 1:2 option at an exercise price of $0.50. These funds are to support a key asset purchase, targeted R&D, working capital, pursue US prescription market expansion opportunities and IPO costs. An IPO is planned for late November 2021 providing Pre-IPO investors a viable exit strategy.
An investment in Xerion gives investors exposure to established large global market opportunities in acne, fungal nail disease, atopic dermatitis, psoriasis and rosacea. These markets are estimated to be worth in excess of US$37B globally.
Xerion is an Australian based specialty pharmaceutical company focusing on key dermatological indications using its proprietary active ingredient, AMYCOT®. Xerion has a CONSUMER HEALTH division focusing on Over the Counter (OTC) sales in Australia and select international markets as well as a PRESCRIPTION division aimed at the lucrative USA market.
Xerion’s first product, nailKALM® is designed for the treatment of Onychomycosis (fungal nail disease) and is sold as an OTC product in Australia. The product is clinically proven and TGA listed to treat fungal nail disease. Chemist Warehouse is our largest Australian customer and have recently launched an exciting national TV campaign that showcases the unique benefits of nailKALM® – Chemist Warehouse nailKALM TVC – June 2021 . nailKALM® is also sold directly to podiatrists.
About Xerion Limited
Xerion is an Australian based specialty pharmaceutical company whose focus is to build a US prescription drug pipeline of 5 new products using AMYCOT® for key dermatological indications.
AMYCOT® is a powerful natural ingredient derived from a strain of spirulina (Arthrospira maxima). AMYCOT® has been shown to have excellent anti-inflammatory, anti-bacterial, anti-fungal and skin regenerative properties through extensive pre-clinical and clinical evidence. This proprietary technology is naturally derived, has no reported significant side effects and is cost effective to produce.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
